Photronics Reports Strong Q1 Results, Guides Q2 Revenue and EPS Sequentially Lower
summarizeSummary
Photronics reported better-than-expected Q1 fiscal 2026 results with record high-end IC revenue, but provided Q2 guidance that projects a sequential decline in both revenue and non-GAAP EPS.
check_boxKey Events
-
Strong Q1 Fiscal 2026 Performance
Photronics reported Q1 fiscal 2026 revenue of $225.1 million, up 6.1% year-over-year and 4.3% sequentially. Non-GAAP diluted EPS reached $0.61, an increase from $0.60 in Q4 2025 and $0.52 in Q1 2025.
-
Record High-End IC Revenue
The company achieved record high-end IC revenue for the second consecutive quarter, reaching $71.3 million, reflecting strong demand for advanced geometries.
-
Q2 Fiscal 2026 Guidance Projects Sequential Decline
For Q2 fiscal 2026, Photronics expects revenue between $212 million and $220 million, a sequential decrease from Q1. Non-GAAP diluted EPS is projected to be between $0.49 and $0.55, also a sequential decline from Q1's $0.61.
-
Significant Capital Expenditure Plans
The company targets approximately $330 million in capital expenditures for fiscal 2026 to expand U.S. and South Korea operations and for end-of-life tool upgrades, indicating continued investment in growth.
auto_awesomeAnalysis
Photronics delivered robust first-quarter fiscal 2026 results, surpassing prior quarter and prior year figures for both revenue and non-GAAP diluted EPS, driven by record high-end IC revenue. However, the company's guidance for the second quarter projects a sequential decline in both revenue and non-GAAP EPS. This forward-looking slowdown, despite strong current performance and the stock trading near its 52-week high, could temper investor enthusiasm. Investors should monitor the company's ability to execute on its significant capital expenditure plans for expansion and how the market reacts to the decelerating guidance.
At the time of this filing, PLAB was trading at $39.50 on NASDAQ in the Manufacturing sector, with a market capitalization of approximately $2.2B. The 52-week trading range was $16.46 to $39.80. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.